Section I INTRODUCTION TO DRUG THERAPY |
|
1 | (50) |
|
Introduction to Pharmacology |
|
|
3 | (8) |
|
|
4 | (1) |
|
|
4 | (1) |
|
Sources of Drug Information |
|
|
4 | (1) |
|
Federal Drug Laws and Standards |
|
|
5 | (1) |
|
|
6 | (1) |
|
Cellular Injury and Response to Injury |
|
|
7 | (4) |
|
Basic Concepts and Processes |
|
|
11 | (11) |
|
Mechanisms of Drug Movement |
|
|
12 | (1) |
|
|
12 | (2) |
|
|
14 | (2) |
|
Variables That Affect Drug Actions |
|
|
16 | (4) |
|
|
20 | (1) |
|
Tolerance and Cross-Tolerance |
|
|
21 | (1) |
|
Administering Medications |
|
|
22 | (14) |
|
Preventing Medication Errors |
|
|
23 | (1) |
|
|
24 | (1) |
|
|
24 | (1) |
|
Drug Preparations and Dosage Forms |
|
|
24 | (1) |
|
|
25 | (2) |
|
|
27 | (9) |
|
Nursing Process in Drug Therapy |
|
|
36 | (15) |
|
Using the Prototype Approach to Study Pharmacology |
|
|
37 | (1) |
|
Legal Responsibilities of the Nurse |
|
|
38 | (1) |
|
Applying the Nursing Process in Drug Therapy |
|
|
38 | (3) |
|
Integrating Nursing Process, Drug Therapy, and Clinical Pathways |
|
|
41 | (1) |
|
General Principles of Drug Therapy |
|
|
41 | (10) |
Section II DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM |
|
51 | (156) |
|
Physiology of the Central Nervous System |
|
|
53 | (8) |
|
Characteristics and Functions of the CNS |
|
|
54 | (6) |
|
|
60 | (1) |
|
Narcotic Analgesics and Narcotic Antagonists |
|
|
61 | (17) |
|
|
62 | (1) |
|
Endogenous Analgesia System |
|
|
63 | (1) |
|
|
63 | (1) |
|
Classifications and Individual Drugs |
|
|
63 | (4) |
|
|
67 | (3) |
|
|
70 | (8) |
|
Analgesic-Antipyretic-Anti-inflammatory and Related Drugs |
|
|
78 | (16) |
|
|
79 | (1) |
|
|
79 | (1) |
|
|
80 | (1) |
|
|
80 | (1) |
|
Contraindications for Use |
|
|
80 | (1) |
|
|
81 | (6) |
|
|
87 | (7) |
|
Antianxiety and Sedative-Hypnotic Drugs |
|
|
94 | (16) |
|
|
95 | (1) |
|
|
95 | (1) |
|
Drugs Used to Treat Anxiety and Insomnia |
|
|
95 | (4) |
|
|
99 | (1) |
|
|
100 | (1) |
|
Contraindications for Use |
|
|
100 | (2) |
|
Principles of Therapy: Benzodiazepines |
|
|
102 | (8) |
|
|
110 | (16) |
|
|
111 | (1) |
|
|
111 | (1) |
|
|
112 | (1) |
|
Individual Antipsychotic Drugs |
|
|
113 | (6) |
|
|
119 | (7) |
|
|
126 | (15) |
|
|
127 | (1) |
|
|
128 | (3) |
|
Individual Antidepressants |
|
|
131 | (2) |
|
|
133 | (8) |
|
|
141 | (13) |
|
|
142 | (1) |
|
|
142 | (1) |
|
Individual Anticonvulsant Drugs |
|
|
143 | (4) |
|
|
147 | (7) |
|
|
154 | (9) |
|
|
155 | (1) |
|
|
155 | (1) |
|
Individual Antiparkinson Drugs |
|
|
156 | (2) |
|
|
158 | (5) |
|
Skeletal Muscle Relaxants |
|
|
163 | (6) |
|
Skeletal Muscle Relaxants |
|
|
164 | (2) |
|
|
166 | (3) |
|
|
169 | (15) |
|
|
170 | (1) |
|
|
170 | (1) |
|
|
171 | (1) |
|
Individual Anesthetic Agents |
|
|
172 | (5) |
|
|
177 | (7) |
|
Alcohol and Other Drug Abuse |
|
|
184 | (16) |
|
|
185 | (1) |
|
|
186 | (6) |
|
|
192 | (2) |
|
|
194 | (1) |
|
|
195 | (1) |
|
Volatile Solvents (Inhalants) |
|
|
196 | (1) |
|
|
197 | (3) |
|
Central Nervous System Stimulants |
|
|
200 | (7) |
|
|
201 | (1) |
|
|
201 | (1) |
|
|
201 | (1) |
|
Contraindications for Use |
|
|
201 | (1) |
|
Individual CNS Stimulants |
|
|
201 | (2) |
|
|
203 | (4) |
Section III DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM |
|
207 | (52) |
|
Physiology of the Autonomic Nervous System |
|
|
209 | (5) |
|
The Autonomic Nervous System |
|
|
210 | (3) |
|
Characteristics of Autonomic Drugs |
|
|
213 | (1) |
|
|
214 | (12) |
|
|
215 | (1) |
|
Individual Adrenergic Drugs |
|
|
216 | (4) |
|
|
220 | (6) |
|
|
226 | (14) |
|
|
227 | (2) |
|
Individual Antiadrenergic Drugs |
|
|
229 | (4) |
|
|
233 | (7) |
|
|
240 | (8) |
|
|
240 | (1) |
|
Individual Cholinergic Drugs |
|
|
240 | (4) |
|
|
244 | (4) |
|
|
248 | (11) |
|
|
249 | (2) |
|
Individual Anticholinergic Drugs |
|
|
251 | (2) |
|
|
253 | (6) |
Section IV DRUGS AFFECTING THE ENDOCRINE SYSTEM |
|
259 | (114) |
|
Physiology of the Endocrine System |
|
|
261 | (5) |
|
|
262 | (1) |
|
Endocrine System-Nervous System Interactions |
|
|
262 | (1) |
|
General Characteristics of Hormones |
|
|
262 | (3) |
|
General Characteristics of Hormonal Drugs |
|
|
265 | (1) |
|
Hypothalamic and Pituitary Hormones |
|
|
266 | (9) |
|
|
267 | (1) |
|
|
268 | (1) |
|
Individual Hormonal Agents |
|
|
268 | (3) |
|
|
271 | (4) |
|
|
275 | (20) |
|
Endogenous Corticosteroids |
|
|
276 | (2) |
|
Exogenous Corticosteroids (Glucocorticoids) |
|
|
278 | (8) |
|
|
286 | (9) |
|
Thyroid and Antithyroid Drugs |
|
|
295 | (13) |
|
|
296 | (1) |
|
|
296 | (3) |
|
|
299 | (3) |
|
|
302 | (6) |
|
Hormones That Regulate Calcium and Phosphorus Metabolism |
|
|
308 | (14) |
|
|
309 | (2) |
|
|
311 | (2) |
|
Principles of Therapy: Drugs Used in Hypocalcemia |
|
|
313 | (2) |
|
|
315 | (3) |
|
Principles of Therapy: Drugs Used in Hypercalcemia |
|
|
318 | (4) |
|
|
322 | (29) |
|
|
323 | (2) |
|
|
325 | (3) |
|
|
328 | (8) |
|
|
336 | (15) |
|
Estrogens, Progestins, and Oral, Contraceptives |
|
|
351 | (14) |
|
|
352 | (1) |
|
|
353 | (1) |
|
Estrogens and Progestins Used as Drugs |
|
|
353 | (1) |
|
Individual Estrogens, Progestins, and Oral Contraceptives |
|
|
354 | (5) |
|
|
359 | (6) |
|
Androgens and Anabolic Steroids |
|
|
365 | (8) |
|
|
366 | (1) |
|
|
366 | (1) |
|
|
366 | (1) |
|
Abuse of Androgenic and Anabolic Steroid Drugs |
|
|
367 | (1) |
|
Characteristics of Androgenic and Anabolic Steroid Drugs |
|
|
367 | (3) |
|
|
370 | (3) |
Section V NUTRIENTS, FLUIDS, AND ELECTROLYTES |
|
373 | (60) |
|
Nutritional Products, Anorexiants, and Digestants |
|
|
375 | (17) |
|
|
376 | (1) |
|
|
376 | (1) |
|
Individual Nutrititional Products for Oral or Tube Feeding |
|
|
376 | (6) |
|
|
382 | (1) |
|
|
383 | (1) |
|
|
384 | (8) |
|
|
392 | (16) |
|
|
393 | (10) |
|
|
403 | (5) |
|
Minerals and Electrolytes |
|
|
408 | (25) |
|
|
409 | (2) |
|
Individual Agents Used in Mineral-Electrolyte and Acid-Base Imbalances |
|
|
411 | (12) |
|
|
423 | (10) |
Section VI DRUGS USED TO TREAT INFECTIONS |
|
433 | (122) |
|
General Characteristics of Antimicrobial Drugs |
|
|
435 | (19) |
|
Microorganisms and Infections |
|
|
436 | (5) |
|
|
441 | (2) |
|
Characteristics of Anti-infective Drugs |
|
|
443 | (3) |
|
|
446 | (8) |
|
Beta-Lactam Antibacterials: Penicillins, Cephalosporins, and Others |
|
|
454 | (18) |
|
|
455 | (1) |
|
|
455 | (1) |
|
|
455 | (8) |
|
|
463 | (1) |
|
|
464 | (1) |
|
|
464 | (1) |
|
Principles of Therapy: Beta-Lactam Antibacterials |
|
|
465 | (7) |
|
Aminoglycosides and Fluoroquinolones |
|
|
472 | (11) |
|
|
473 | (3) |
|
|
476 | (1) |
|
Principles of Therapy: Aminoglycosides and Fluoroquinolones |
|
|
477 | (6) |
|
Tetracyclines, Sulfonamides and Urinary Agents |
|
|
483 | (12) |
|
|
484 | (5) |
|
|
489 | (1) |
|
|
490 | (1) |
|
Principles of Therapy: Tetracyclines |
|
|
491 | (1) |
|
Principles of Therapy: Sulfonamides and Urinary Antiseptics |
|
|
491 | (4) |
|
Macrolides and Miscellaneous Antibacterials |
|
|
495 | (11) |
|
|
496 | (1) |
|
Miscellaneous Antibacterial Drugs |
|
|
497 | (3) |
|
Principles of Therapy: Macrolides and Miscellaneous Antibacterials |
|
|
500 | (6) |
|
Drugs for Tuberculosis and Mycobacterium Avium Complex (MAC) Disease |
|
|
506 | (12) |
|
|
507 | (1) |
|
Prevention and Treatment of Tuberculosis |
|
|
507 | (1) |
|
Characteristics of Antitubercular Drugs |
|
|
508 | (1) |
|
Individual Antitubercular Drugs |
|
|
509 | (2) |
|
Mycobacterium avium Complex (MAC) Disease |
|
|
511 | (1) |
|
|
512 | (6) |
|
|
518 | (16) |
|
General Characteristics of Viruses and Viral Infections |
|
|
519 | (1) |
|
|
519 | (8) |
|
|
527 | (7) |
|
|
534 | (8) |
|
Fungi and Fungal Infections |
|
|
535 | (1) |
|
|
535 | (3) |
|
|
538 | (4) |
|
|
542 | (13) |
|
|
543 | (1) |
|
|
544 | (1) |
|
|
545 | (1) |
|
Individual Antiparasitic Drugs |
|
|
545 | (6) |
|
|
551 | (4) |
Section VII DRUGS AFFECTING THE IMMUNE SYSTEM |
|
555 | (58) |
|
Physiology of the Immune System |
|
|
557 | (10) |
|
Overview of Body Defence Mechanisms |
|
|
558 | (1) |
|
|
558 | (1) |
|
|
559 | (5) |
|
Patient-Related Factors That Influence Immune Function |
|
|
564 | (1) |
|
|
565 | (1) |
|
|
566 | (1) |
|
|
567 | (18) |
|
|
568 | (1) |
|
Agents for Active Immunity |
|
|
568 | (1) |
|
Agents for Passive Immunity |
|
|
568 | (1) |
|
Individual Immunizing Agents |
|
|
568 | (12) |
|
|
580 | (5) |
|
|
585 | (11) |
|
|
586 | (4) |
|
Individual Immunostimulants |
|
|
590 | (1) |
|
|
591 | (5) |
|
|
596 | (17) |
|
|
597 | (1) |
|
|
597 | (1) |
|
Tissue and Organ Transplantation |
|
|
597 | (3) |
|
|
600 | (1) |
|
|
600 | (4) |
|
|
604 | (9) |
Section VIII DRUGS AFFECTING THE RESPIRATORY SYSTEM |
|
613 | (36) |
|
Physiology of the Respiratory System |
|
|
615 | (3) |
|
|
616 | (1) |
|
Disorders of the Respiratory System |
|
|
617 | (1) |
|
|
617 | (1) |
|
Bronchodilating and Antiasthmatic Drugs |
|
|
618 | (13) |
|
|
619 | (1) |
|
|
619 | (1) |
|
Individual Bronchodilating and Antiasthmatic Drugs |
|
|
620 | (5) |
|
|
625 | (6) |
|
|
631 | (9) |
|
Histamine and Its Receptors |
|
|
632 | (1) |
|
|
632 | (4) |
|
|
636 | (4) |
|
Nasal Decongestants, Antitussives, Mucolytics, and Cold Remedies |
|
|
640 | (9) |
|
|
641 | (1) |
|
|
642 | (2) |
|
|
644 | (5) |
Section IX DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM |
|
649 | (110) |
|
Physiology of the Cardiovascular System |
|
|
651 | (4) |
|
|
652 | (1) |
|
|
652 | (1) |
|
|
653 | (1) |
|
Drug Therapy in Cardiovascular Disorders |
|
|
653 | (2) |
|
Cardiotonic-Inotropic Agents Used in Congestive Heart Failure |
|
|
655 | (12) |
|
|
656 | (1) |
|
|
656 | (4) |
|
|
660 | (7) |
|
|
667 | (17) |
|
|
668 | (1) |
|
|
668 | (1) |
|
|
668 | (3) |
|
|
671 | (1) |
|
Classifications and Individual Drugs |
|
|
671 | (8) |
|
|
679 | (5) |
|
|
684 | (11) |
|
|
685 | (1) |
|
|
685 | (2) |
|
Individual Antianginal Drugs |
|
|
687 | (3) |
|
|
690 | (5) |
|
Drugs Used in Hypotension and Shock |
|
|
695 | (7) |
|
|
696 | (1) |
|
|
696 | (1) |
|
Individual Drugs Used in Hypotension and Shock |
|
|
696 | (2) |
|
|
698 | (4) |
|
|
702 | (19) |
|
Regulation of Arterial Blood Pressure |
|
|
703 | (1) |
|
|
703 | (1) |
|
|
704 | (2) |
|
|
706 | (7) |
|
|
713 | (8) |
|
|
721 | (13) |
|
|
722 | (1) |
|
|
722 | (3) |
|
Alterations in Renal Function |
|
|
725 | (1) |
|
|
725 | (3) |
|
|
728 | (6) |
|
Anticoagulant, Antiplatelet, and Thrombolytic Agents |
|
|
734 | (14) |
|
|
735 | (1) |
|
|
735 | (1) |
|
Thrombotic and Thromboembolic Disorders |
|
|
735 | (1) |
|
Drugs Used in Thrombotic and Thromboembolic Disorders |
|
|
736 | (1) |
|
|
737 | (4) |
|
|
741 | (7) |
|
Antilipemics and Peripheral Vasodilators |
|
|
748 | (11) |
|
Antilipemic Drugs and Peripheral Vasodilators |
|
|
749 | (1) |
|
|
749 | (1) |
|
|
749 | (2) |
|
|
751 | (1) |
|
Drugs Used to Treat Hyperlipidemia |
|
|
751 | (3) |
|
|
754 | (5) |
Section X DRUGS AFFECTING THE DIGESTIVE SYSTEM |
|
759 | (50) |
|
Physiology of the Digestive System |
|
|
761 | (4) |
|
|
762 | (1) |
|
Organs of the Digestive System |
|
|
762 | (1) |
|
Secretions of the Digestive System |
|
|
762 | (2) |
|
Effects of Drugs on the Digestive System |
|
|
764 | (1) |
|
Drugs Used in Peptic Ulcer Disease |
|
|
765 | (15) |
|
|
766 | (1) |
|
|
766 | (8) |
|
|
774 | (6) |
|
|
780 | (9) |
|
|
781 | (1) |
|
|
781 | (1) |
|
|
781 | (4) |
|
|
785 | (4) |
|
|
789 | (11) |
|
|
790 | (6) |
|
|
796 | (4) |
|
|
800 | (9) |
|
|
801 | (1) |
|
|
801 | (4) |
|
|
805 | (4) |
Section XI DRUGS USED IN SPECIAL CONDITIONS |
|
809 | (78) |
|
|
811 | (24) |
|
Characteristics of Normal Cells |
|
|
812 | (1) |
|
Characteristics of Malignant Neoplasms |
|
|
812 | (4) |
|
Characteristics of Antineoplastic Drugs |
|
|
816 | (2) |
|
|
818 | (5) |
|
Drugs That Reduce Toxicity of Antineoplastic Drugs |
|
|
823 | (4) |
|
|
827 | (8) |
|
Drugs Used in Ophthalmic Conditions |
|
|
835 | (16) |
|
|
836 | (1) |
|
|
836 | (1) |
|
|
837 | (1) |
|
|
838 | (7) |
|
|
845 | (6) |
|
Drugs Used in Dermatologic Conditions |
|
|
851 | (17) |
|
|
852 | (1) |
|
|
852 | (2) |
|
Types of Dermatologic Drugs |
|
|
854 | (1) |
|
|
855 | (8) |
|
|
863 | (5) |
|
Drug Use During Pregnancy and Lactation |
|
|
868 | (19) |
|
|
869 | (1) |
|
Maternal-Placental-Fetal Circulation |
|
|
869 | (1) |
|
Drug Effects on the Fetus |
|
|
870 | (1) |
|
|
870 | (1) |
|
|
870 | (7) |
|
|
877 | (1) |
|
|
878 | (1) |
|
Drugs Used During Labor and Delivery at Term |
|
|
879 | (1) |
|
|
879 | (1) |
|
|
880 | (7) |
Appendix A: Miscellaneous Drugs |
|
887 | (2) |
Appendix B: The International System of Units |
|
889 | (1) |
Appendix C: Therapeutic Serum Drug Concentrations for Selected Drugs |
|
890 | (1) |
Appendix D: Canadian Drug Laws and Standards |
|
891 | (1) |
Appendix E: Canadian Drug Names |
|
892 | (8) |
Index |
|
900 | |